POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk Group

Video

This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.

In this video, Katja Weisel, MD, of the University of Tübingen in Germany, reviews updated results of two phase III trials in relapsed or refractory multiple myeloma that revealed the impact of daratumumab combinations across cytogenetic risk groups.

POLLUX tested daratumumab in combination with lenalidomide plus dexamethasone (DRd) vs lenalidomide plus dexamethasone (Rd). Patients on this trial had a median of 1 prior treatment.

CASTOR tested daratumumab in combination with bortezomib plus dexamethasone (DVd) vs bortezomib plus dexamethasone (Vd). Patients on this trial had a median of 2 prior treatments and 42% of patients had already been treated with lenalidomide.

Weisel presented results of the study (abstract 8006) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Related Videos
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content